Abstract
In December 2019, the world was confronted with the outbreak of the respiratory disease COVID-19. The COVID-19 epidemic evolved at the beginning of 2020 into a pandemic, which continues to this day. The incredible speed of the spread and the consequences of the infection had a worldwide impact on societies and health systems. Governments enforced many measures to control the COVID-19 pandemic: Restrictions (e.g. lockdown), medical care (e.g. intensive care) and medical prevention (e.g. hygiene concept). This leads to a different spreading behavior of the COVID-19 pandemic, depending on measures. Furthermore, the spreading behavior is influenced by culture and geographical impacts. The spreading behavior of COVID-19 related to short time intervals can be described by Weibull distribution models, common in reliability engineering, in a sound way. The interpretation of the model parameters allows the assessment of the COVID-19 spreading characteristics. This paper shows results of a research study of the COVID-19 spreading behavior depending on different pandemic time phases within Germany and Japan. Both countries are industrial nations, but have many differences with respect to historical development, culture and geographical conditions. Consequently, the chosen government measures have different impacts on the control of the COVID-19 pandemic. The research study contains the analyses of different pandemic time intervals in Germany and Japan: The breakout phase in spring 2020 and subsequently following waves until winter season 2020/2021.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no fundings
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Wuppertal
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: bracke{at}uni-wuppertal.de
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.